Programme

See below for the provisional programme of the 33rd International Symposium on ALS/MND which will be held virtually on 6 - 9 December 2022.

This includes platform presentations made up of cutting-edge research talks with live Q&As at the end of each session, and discussions from our invited plenary speakers, award presentations, and live poster sessions. Please note that the programme may be subject to change.

The published abstract book will be available in mid-November 2022.

There will also be networking opportunities, industry-led sessions and the ePoster Hall (to preview over 250 posters before the live poster sessions).

DAY 1 (Tuesday 6 December)

SESSION 1: OPENING SESSION
GMTESTJSTPRESENTATIONSPEAKER
1345 - 13500845 - 08502245 - 2250Welcome to the 33rd International Symposium on ALS/MND
1350 - 1435

0850 - 09352250 - 2335The Stephen Hawking Memorial Lecture: Introduction
C1 The contribution of aging to neurodegenerative disease
L Hawking (UK)
F Gage (USA)
1435 - 1445

0935 - 09452335 - 2345Discussion/Questions
1445 - 14550945 - 09552345 - 2355International Alliance of ALS/MND Associations
Forbes Norris and Humanitarian Awards
1455 - 15100955 - 10102355 - 0010IPG Award and winner’s research presentation

ICEBREAKER (30 MINUTES)


 

SESSION 2: CLINICAL TRIALS
GMTESTJSTPRESENTATIONSPEAKER
1540 - 16001040 - 11000040 - 0100C2 Results from a randomized, double-blind, placebo-controlled trial of RNS60 in people with ALSE Pupillo (Italy)
1600 - 16201100 - 11200100 - 0120C3 Efficacy and safety of low dose IL-2 in ALS: The MIROCALS trialG Bensimon (France)
1620 - 16301120 - 11300120 - 0130C4 Evidence for a survival benefit in ALS with CNM-Au8 treatment: interim results from the RESCUE-ALS trial long-term open extensionS Vucic (Australia)
1630 - 16401130 - 11400130 - 0140C5 Evaluating efficacy and safety of Tofersen in adults with SOD1 ALS: Results from the Phase 3 VALOR trial and open label extensionT Miller (USA)
1640 - 16551140 - 11550140 - 0155Discussion/Questions

BREAK (10 MINUTES)


 


LIVE POSTER SESSION A

GMT 17:05 - 18:35   |   EST 12:05 - 13:35   |   JST 02:05 - 03:35

 

 

DAY 2 (Wednesday 7 December)


LIVE POSTER SESSION B

GMT 12:15 - 13:45   |   EST 07:15 - 08:45   |   JST 21:15 - 22:45

 


BREAK (15 MINUTES)


 

SESSION 3: METABOLISM
GMTESTJSTPRESENTATIONSPEAKERPARALLEL SESSION
1400- 14250900- 09252300- 2325C6 Investigating the role of hypermetabolism in ALSS Ngo (Australia)1400-1445Interactive Industry Session (non-CME)
1425- 1440
0925- 09402325- 2340C7 Dysregulated energy metabolism related to worse prognosis in ALSJ He (China)
1440- 14550940- 09552340- 2355C8 An 18F-FDG-PET study exploring the metabolic signature of pure bulbar and pure spinal ALSF Di Pede (Italy)
1455- 15100955- 10102355- 0010Discussion/Questions

NETWORKING (30 MINUTES)


 

SESSION 4: CELL BASED MODELS
GMTESTJSTPRESENTATIONSPEAKERPARALLEL SESSION
1540 - 16051025 - 10500025 - 0050C9 iPSC-derived models for compound screening and the identification of new therapeutic strategiesK Roet (USA)1540 - 1625 Interactive Industry Session (non-CME)
1605 - 16201105 - 11200105 - 0120C10 Sporadic ALS motor neurons recapitulate neuronal vulnerabilityB Turner (Australia)
1620 - 16351120 - 11350120 - 0135C11 Reduced C9orf72 expression exacerbates poly-GR toxicity in patient iPSC-derived motor neuronsT Dane (USA)
1635 - 16501135 - 11500135 - 0150Discussion/Questions

BREAK (15 MINUTES)


 

SESSION 5: DISEASE PRESENTATION AND RISK
GMTESTJSTPRESENTATIONSPEAKERPARALLEL SESSION
1705 - 17251205 - 12250205 - 0225C12 Identifying risk factors using Mendelian RandomizationG Davey-Smith (UK)1705 - 1750 Interactive Industry Session (non-CME)
1725 - 17451225 - 12450225 - 0245C13 Traumatic Brain Injury as a risk factor for neurodegenerative diseaseC Tartaglia (Canada)
1745 - 18051245 - 13050245 - 0305C14 Mild motor impairment and prodromal markersM Benatar (USA)
1805 - 18201305 - 13200305 - 0320Discussion/Questions

 

DAY 3 (Thursday 8 December)

SESSION 6: GENETICS AND GENOMICS
GMTESTJSTPRESENTATIONSPEAKERPARALLEL SESSION
1400 - 14250900 - 09252300 - 2325C15 Decoding gene regulatory networks in ALSJ Kirby (UK)1400 - 1445Interactive Industry Session (non-CME)
1425 - 14400925 - 09402325 - 2340C16 Unsupervised hierarchical clustering of postmortem motor cortex expression data identifies distinct molecular phenotypes which replicate the major mechanisms of ALS pathogenesis H Marriott (UK)
1440 - 14550940 - 09552340 - 2355C17 Interactions between genetic modifiers of survival in ALS: a population based studyA Chio (Italy)
1455 - 15100955 - 10102355 - 0010Discussion/Questions

BREAK (15 MINUTES)


 

SESSION 7: RNA AND PROTEIN PROCESSING
GMTESTJSTPRESENTATIONSPEAKERPARALLEL SESSION
1525 - 15501025 - 10500025 - 0050C18 Protein chaperones as a therapeutic target for ALSH Durham (Canada)1525 - 1610Interactive Industry Session (non-CME)
1550 - 16151050 - 11150050 - 0115C19 microRNA dysregulation in motor neuron diseaseE Hornstein (Israel)
1615 - 16301115 - 11300115 - 0130C20 Diminished miRNA activity is associated with aberrant cytoplasmic intron retention in ALS pathogenesisH Crerar (UK)
1630 - 16451130 - 11450130 - 0145Discussion/Questions

BREAK (15 MINUTES)


 


LIVE POSTER SESSION C

GMT 17:00 - 18:30   |   EST 12:00 - 13:30   |   JST 02:00 - 03:30

 

 

DAY 4 (Friday 9 December)


LIVE POSTER SESSION D

GMT 12:15 - 13:45   |   EST 07:15 - 08:45   |   JST 21:15 - 22:45

 


BREAK (15 MINUTES)


 

SESSION 8: NEUROINFLAMMATION
GMTESTJSTPRESENTATIONSPEAKERPARALLEL SESSION
1400 - 14200900 - 09202300 - 2320C21 Modelling neuroinflammation in ALS J Kriz (Canada)1400 - 1445Interactive Industry Session (non-CME)
1420 - 14400920 - 09402320 - 2340C22 Suppressing Neuroinflammation: Regulatory T Lymphocyte Immunomodulatory Therapy for ALS S Appel (USA)
1440 - 14550940 - 09552340 - 2355C23 Molecular signatures of neuroinflammation in patient tissue across sporadic, SOD1 and C9orf72 ALS cohortsO Rifai (UK)
1455 - 15100955 - 10102355 - 0010Discussion/Questions

BREAK (15 MINUTES)


 

SESSION 9: TRIAL DESIGN AND CLINICAL ENDPOINTS
GMTESTJSTPRESENTATIONSPEAKER
1525 - 15451025 - 10450025 - 0045C24 Improving clinical endpoints in therapeutic trials for ALS R van Eijk (Netherlands)
1545 - 16051045 - 11050045 - 0105C25 Improving ALS clinical trial design T Ferguson (USA)
S Fradette (USA)
1605 - 16201105 - 11200105 - 0120C26 Registry of Validated Endpoints in ALS (REVEALS): Results from a multi-centre prospective study of respiratory measures and their clinical meaningfulnessD Meldrum (Ireland)
1620 - 16351120 - 11350120 - 0135Discussion/Questions

BREAK (15 MINUTES)


 

SESSION 10: CLOSING SESSION
GMTESTJSTPRESENTATIONSPEAKER
1650 - 16551150 - 11550150 - 0155Invitation to Basel 2023
1655 - 17251155 - 12250155 - 0225C27 BrainGate: Clinical trials in intracortical brain-computer interfaces toward the restoration of communication and mobilityL Hochberg (USA)
1725 - 17351225 - 12350225 - 0235Discussion/Questions
1735 - 17551235 - 12550235 - 0255Healey Center Award & The Lalji Family ALS Award
1755 - 18151255 - 13150255 - 0315Late breaking news and final thoughts

Symposium Programme Committee

Ammar Al-Chalabi (Chair of Programme Committee), King's College London
Nick Cole, Motor Neurone Disease Association
Brian Dickie, Motor Neurone Disease Association
Albert La Spada, University of California Irvine
Caroline Ingre, Karolinska Institute
Kuldip Dave, The ALS Association
Nick Goldup, Motor Neurone Disease Association
Markus Weber, University of Basel
David Taylor, ALS Canada
Catherine Lomen-hoerth, University of California, San Francisco